Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Simcere Announces $292 Million Deal for Novel Glioblastoma Treatment

publication date: Mar 29, 2021

Simcere Pharma of Nanjing announced a $292 million agreement to develop a proposed Kazia Therapeutics treatment for glioma in Greater China. Paxalisib is a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is disordered in the majority patients with glioblastoma, the most common and most aggressive form of primary brain cancer. Kazia, an Australian company, said paxalisib seemed to be effective in a pivotal Phase II trial among GBM patients, though the trial began less than three months ago. More details....

Stock Symbols: (HK: 2096) (ASX: KZA; NSDQ: KZIA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.